HAS1 and cancer: We and others have previously demonstrated that nutraceutical coumarin derivative 4-methylumbelliferone (4Mu) is capable of selectively modulating the synthesis of HA through the reduction of HAS mRNA levels and by depletion of the HA precursor UDP-glucuronic acid34, leading to different effects both in cancer cells and in the TME40.